SUPPLEMENTAL FIGURES

Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-mediated Drug-Drug Interactions using Statins

L.J. Stevens[1,2], A.Z.X. Zhu[3], P.P. Chothe[4], S.K. Chowdhury[4], J. M. Donkers[2], W.H.J. Vaes[2], C.A.J. Knibbe[5], I.P.J. Alwayn[1] and E. van de Steeg[2]

[1] Department of Surgery, Leiden University Medical Centre (LUMC) Transplant Center, Leiden, the Netherlands

[2] The Netherlands Organization for Applied Scientific Research (TNO), Zeist, the Netherlands

[3] Quantitative Solutions, Takeda Pharmaceutical International, Cambridge, MA, USA

[4] Department of Drug Metabolism & Pharmacokinetics, Takeda Pharmaceuticals International, Cambridge, MA, USA

[5] Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden, the Netherlands & Department of Clinical Pharmacy, St. Antonius Hospital Nieuwegein and Utrecht, the Netherlands

Drug Metabolism and disposition

DMD-AR-2021-000521

Table S2. Details of the LC/MS conditions used for the analysis of atorvastatin and atorvastatin metabolites, pitavastatin, rosuvastatin and rifampicin.

Compound	Column	Mobile Phase A	Mobile Phase B	Time (sec)	Mobile Phase B (%)	Flow (ml/min)
Atorvastatin, atorvastatin lactone, 2-hydroxy atorvastatin, 4-hydroxy-atorvastatin, 4-hydroxy atorvastatin lactone	Macmod; ACE 3 C18-AR; 30x2.1 mm	0.1% Formic Acid in 95:5 Water:Acetonitrile	0.1% Formic Acid in 50:50 Acetonitrile:Methanol	15 (Step) 60 (Ramp) 5 (Ramp) 30 (Step)	45 95 95 95	0.800
Pitavastatin				15 (Step) 60 (Ramp) 5 (Ramp) 30 (Step) 40 (Step)	30 70 95 95 30	
Rosuvastatin				15 (Step) 60 (Ramp) 30 (Step) 40 (Step)	40 80 95 40	
Rifampicin	Waters; Xbridge C8; 50x2.1 mm			30 (Step) 120(Ramp) 50 (Step) 40 (Step)	30 70 95 30	0.700